MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

You Make the Call

The significance of JAK2-positive test results in a healthy patient

This month Josef Prchal, MD, discusses the significance of JAK2-positive test results in a healthy patient. And don't forget to check out next month's clinical dilemma...
You Make the Call

The significance of JAK2-positive test results in a healthy patient

Here’s how readers responded to a You Make the Call question about the significance of JAK2-positive test results in a healthy patient. Disclaimer: ASH does...

Tagraxofusp-erzs Becomes First Approval for BPDCN

The U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children (≥2 years of age) with blastic plasmacytoid dendritic cell...

Transplant or No Transplant for Older, Fit Patients With MDS?

Hematopoietic cell transplantation (HCT) with reduced-intensity conditioning improved overall survival (OS) in older patients with advanced myelodysplastic syndromes (MDS), compared with OS in patients...

An MRD-Guided Azacitidine Treatment Strategy Delays Hematologic Relapse in MDS and AML

According to results from the phase II RELAZA2 trial, minimal residual disease (MRD)–guided treatment with the hypomethylating agent azacitidine delayed hematologic relapse in patients...

Luspatercept Reduces the Need for Transfusions in Patients With Beta Thalassemia and MDS

In two separate phase III trials presented at the 2018 ASH Annual Meeting, luspatercept, a first-in-class recombinant fusion protein, was found to be safe...

Algorithm Built on Big Data Improves Prognostic Accuracy Over Existing MDS Models

Using machine learning, researchers were able to develop a prognostic model that predicted survival among patients with myelodysplastic syndromes (MDS) and was more accurate...
How I Treat In Brief

How I Treat in Brief: Using Molecular Genetic Tests to Evaluate Myelodysplastic Syndromes

David P. Steensma, MD, of Dana-Farber Cancer Institute and Harvard Medical School in Boston, discussed how to use results from molecular genetic tests in...
WIB_icon

No Benefit With Adding Eltrombopag to Azacitidine in Patients With Higher-Risk MDS

In the phase III SUPPORT trial, researchers tested the hypothesis that concomitant administration of the thrombopoietin receptor agonist eltrombopag could ameliorate the thrombocytopenic effects...

Researchers Identify Genetic Prognostic Predictors in Myeloproliferative Neoplasms

A team of European and American researchers have identified and characterized associations between specific genetic mutations and prognosis in patients with myeloproliferative neoplasms (MPNs),...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.